

IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Bruno MOUGIN et al.

Group Art Unit: 1656

Application No.: 10/594,584

Filed: September 27, 2006

Docket No.: 129432

For: METHOD FOR THE PROGNOSIS AND/OR DIAGNOSIS OF A CANCER

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 2. Relevance of one or more non-English language reference is discussed in the present specification. See References 10, 12-15 and 18-20. Reference 20 is incorrectly cited in the specification as WO 99/15321.
- 3. One or more reference cited herein was cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. See References 21 and 23-27.
- 4. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.
- 5. An English language Abstract of one or more non-English language reference is attached hereto. See References 12-15 and 18-20.

6. References 8 and 9 correspond to reference 21.

Respectfully submitted,



William P. Berridge
Registration No. 30,024

Kristin K. Vidovich
Registration No. 41,448

WPB:KKV/ejw

Date: November 29, 2006

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--



Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 129432	APPLICATION NO. 10/594,584
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Bruno MOUGIN et al.	
				FILING DATE September 27, 2006	GROUP 1656
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Date	Name	
	1	5,234,809	08/10/1993	BOOM et al.	
	2	4,672,040	06/09/1987	JOSEPHSON	
	3	5,750,338	05/12/1998	COLLINS et al.	
	4	4,683,195	07/28/1987	MULLIS et al.	
	5	4,683,202	07/28/1987	MULLIS	
	6	4,800,159	01/24/1989	MULLIS et al.	
	7	5,399,491	03/21/1995	KACIAN et al.	
	8	2003/0138783	07/24/2003	SUKUMAR et al.	
	9	2003/0017454	01/23/2003	SUKUMAR et al.	
FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract With English Translation
	10	FR 2 780 059	12/24/1999	FRANCE	
	11	EP 0 201 184 A2	12/17/1986	EUROPE	
	12	WO 00/05338	02/03/2000	WIPO	X
	13	WO 99/53304	10/21/1999	WIPO	X
	14	WO 97/45202	12/04/1997	WIPO	X
	15	WO 99/35500	07/15/1999	WIPO	X
	16	WO 90/01069	02/08/1990	WIPO	
	17	WO 90/06995	06/28/1990	WIPO	
	18	WO 91/19812	12/26/1991	WIPO	X
	19	WO 95/08000	03/23/1995	WIPO	X
	20	WO 99/15621	04/01/1999	WIPO	X
	21	WO 02/059347	08/01/2002	WIPO	
	22	WO 91/02818	03/07/1991	WIPO	
EXAMINER				DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 129432	APPLICATION NO. 10/594,584
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT(S) Bruno MOUGIN et al.		
		FILING DATE September 27, 2006	GROUP 1656	
OTHER DOCUMENTS				
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)		
	23	Martin T. et al., "Elevated Expression of Transcription Regulatory Proteins Twist and Slug in Human Breast Cancer and Their Clinical Significance," Breast Cancer Research and Treatment, vol. 82, No. SUPPL 1, 3 December 2003, pp. S117-S118 (abstracts-poster session IV).		
	24	Wang X. et al., "Identification of a Novel Function of Twist, a bHLH Protein, in the Development of Acquired Taxol Resistance in Human Cancer Cells," ONCOGENE, vol. 23, no. 2, January 2004, pp. 472-82.		
	25	Qadoumi M. et al., "Identification of Signature Genes for Leukemic CTCL Cells in S?ry Syndrome," Archives of Dermatological Research, vol. 295, No. 8/9, 26 February 2004, p. 380 (abstract).		
	26	Yang J. et al., "Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis," CELL, vol. 117, 25 June 2004, pp. 927-939.		
	27	Valsesia-Wittmann S., et al., "Oncogenic Cooperation Between H-Twist and N-Myc Overrides Failsafe Programs in Cancer Cells," CANCER CELL, vol. 6, No. 6, December 2004, pp. 625-630.		
	28	Brodeur, G. et al., "Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment," Journal of Clinical Oncology, Vol. 11, No. 8, August 1993, pp. 1466-1477.		
	29	Rubie, H. et al., "N-Myc Gene Amplification Is a Major Prognostic Factor in Localized Neuroblastoma: Results of the French NBL 90 Study," Journal of Clinical Oncology, Vol. 15, No. 3, March 1997, pp. 1171-1182.		
	30	Seeger, R. et al., "Association of Multiple Copies of the N-Myc Oncogene with Rapid Progression of Neuroblastomas," The New England Journal of Medicine, Vol. 313, No. 18, 31 October 1985, pp. 1111-1116.		
	31	Slamon, D. et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of HER-2/neu Oncogene," SCIENCE, Vol. 235, 9 January 1987, pp. 177-182.		
	32	Tyagi S. et al., "Molecular Beacons: Probes that Fluoresce upon Hybridization," Nature Biotechnology, Vol. 14, March 1996, pp. 303-308.		
EXAMINER				DATE CONSIDERED
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 129432	APPLICATION NO. 10/594,584
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				
		APPLICANT(S) Bruno MOUGIN et al.		
		FILING DATE September 27, 2006	GROUP 1656	
OTHER DOCUMENTS				
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)		
	33	Keller, R. et al., "Non-Radioactive Filter Hybridization Conditions," DNA Probes, Section Five: Hybridization Formats and Detection Procedures, 2 nd Edition, Stockton Press, 1993, pp. 173-249.		
	34	Giulietti, A. et al., "An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression," Methods, Vol. 25, 2001, pp. 386-401.		
	35	Levison, P. et al., "New Approaches to the Isolation of DNA by Ion-Exchange Chromatography," Journal of Chromatography A, vol. 827, 1998, pp. 337-344.		
	36	Holland, P. et al., "Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5'→3' Exonuclease Activity of <i>Thermus aquaticus</i> DNA Polymerase," Proc. Nalt. Acad. Sci., Vol. 88, August 1991, pp. 7276-7280.		
	37	Bustin, S., "Quantification of mRNA Using Real-Time Reverse Transcription PCR (RT-PCR): Trends and Problems," Journal of Molecular Endocrinology, Vol. 29, 2002, pp. 23-39.		
	38	Boom, R. et al., "Rapid and Simple Method for Purification of Nucleic Acids," Journal of Clinical Microbiology, Vol. 28, No. 3, March 1990, pp. 495-503.		
	39	Kricka, L., "Nucleic Acid Detection Technologies-Labels, Strategies, and Formats," Clinical Chemistry, Vol. 45, No. 4, 1999, pp. 453-458.		
EXAMINER				DATE CONSIDERED
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				